A team from Peking Union Medical College Hospital in Beijing has published a review in the World Journal of Pediatrics (DOI: 10.1007/s12519-026-01035-4) that formalizes a framework for Behçet’s spectrum disorders (BSD), a concept first introduced in 2020. The framework aims to help clinicians recognize Behçet-like inflammation earlier and prioritize genetic testing in children whose symptoms fall outside classic diagnostic patterns.
Behçet’s disease (BD) is a systemic vasculitis marked by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. A growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms, yet they are biologically distinct and require different therapeutic approaches. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering.
The researchers propose a tiered classification: “core BSD” for monogenic diseases that directly converge on Behçet’s-defining inflammatory pathways, and “peripheral BSD” for conditions with partial clinical overlap or indirect mechanistic connections. Core BSD includes HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency—all disrupting NF-κB or JAK-STAT signaling. Peripheral BSD encompasses polygenic or multifactorial entities such as recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease.
A major highlight is the identification of NF-κB and JAK-STAT as two central inflammatory hubs that serve as common denominators across the entire spectrum, providing a rational basis for grouping these diverse disorders. The authors also delineate exclusion criteria, distinguishing true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations, thereby sharpening diagnostic boundaries.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL-1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism-based trials.
“We’re not saying these are all the same disease—they’re not,” the authors said. “But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn’t quite fit Behçet’s criteria, the BSD framework gives us a roadmap for what to test for and why.” They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
This systematic review establishes a two‑tier BSD classification grounded in genetic and mechanistic evidence. The goal is not to replace existing diagnostic criteria but to provide a mechanism-oriented lens for earlier recognition and genetic screening in children with Behçet-like presentations. Ultimately, this framework empowers pediatricians to move beyond trial‑and‑error management towards precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment.
